Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1α: modulation by p38 MAPK

  1. Melina Fan1,
  2. James Rhee1,
  3. Julie St-Pierre1,
  4. Christoph Handschin1,
  5. Pere Puigserver2,
  6. Jiandie Lin1,
  7. Sibylle Jäeger1,
  8. Hediye Erdjument-Bromage3,
  9. Paul Tempst3, and
  10. Bruce M. Spiegelman1,4
  1. 1Dana-Farber Cancer Institute and the Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA; 2Johns Hopkins University Medical School, Baltimore, Maryland 21205, USA; 3Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA

Abstract

The transcriptional coactivator PPAR gamma coactivator 1 α (PGC-1α) is a key regulator of metabolic processes such as mitochondrial biogenesis and respiration in muscle and gluconeogenesis in liver. Reduced levels of PGC-1α in humans have been associated with type II diabetes. PGC-1α contains a negative regulatory domain that attenuates its transcriptional activity. This negative regulation is removed by phosphorylation of PGC-1α by p38 MAPK, an important kinase downstream of cytokine signaling in muscle and β-adrenergic signaling in brown fat. We describe here the identification of p160 myb binding protein (p160MBP) as a repressor of PGC-1α. The binding and repression of PGC-1α by p160MBP is disrupted by p38 MAPK phosphorylation of PGC-1α. Adenoviral expression of p160MBP in myoblasts strongly reduces PGC-1α's ability to stimulate mitochondrial respiration and the expression of the genes of the electron transport system. This repression does not require removal of PGC-1α from chromatin, suggesting that p160MBP is or recruits a direct transcriptional suppressor. Overall, these data indicate that p160MBP is a powerful negative regulator of PGC-1α function and provide a molecular mechanism for the activation of PGC-1α by p38 MAPK. The discovery of p160MBP as a PGC-1α regulator has important implications for the understanding of energy balance and diabetes.

Keywords

Footnotes

  • Article published online ahead of print. Article and publication date are at http://www.genesdev.org/cgi/doi/10.1101/gad.1152204.

  • Supplemental material is available at http://www.genesdev.org.

  • 4 Corresponding author. E-MAIL bruce_spiegelman{at}dfci.harvard.edu; FAX (617) 632-5363.

    • Accepted December 11, 2003.
    • Received September 15, 2003.
| Table of Contents

Life Science Alliance